Zosano Pharma Stock Price, News & Analysis (NASDAQ:ZSAN)

$4.35 -0.34 (-7.25 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$4.69
Today's Range$4.27 - $4.84
52-Week Range$3.61 - $60.00
Volume33,175 shs
Average Volume81,782 shs
Market Capitalization$9 million
P/E Ratio-0.19
Dividend YieldN/A
Beta1.89

About Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma logoZosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ZSAN
CUSIPN/A
Phone+1-510-7451200

Debt

Debt-to-Equity RatioN/A
Current Ratio2.26%
Quick Ratio2.26%

Price-To-Earnings

Trailing P/E Ratio-0.193712829226848
Forward P/E Ratio-0.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$310,000.00
Price / Sales27.64
Cash FlowN/A
Price / CashN/A
Book Value$5.33 per share
Price / Book0.82

Profitability

Trailing EPS($23.54)
Net Income$-29,830,000.00
Net MarginsN/A
Return on Equity-169.79%
Return on Assets-94.28%

Miscellaneous

Employees38
Outstanding Shares1,970,000

Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Zosano Pharma shares reverse split before market open on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) issued its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($4.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.00) by $1.00. View Zosano Pharma's Earnings History.

When will Zosano Pharma make its next earnings announcement?

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Zosano Pharma.

Where is Zosano Pharma's stock going? Where will Zosano Pharma's stock price be in 2018?

2 brokerages have issued twelve-month price targets for Zosano Pharma's shares. Their predictions range from $60.00 to $80.00. On average, they anticipate Zosano Pharma's stock price to reach $70.00 in the next year. View Analyst Ratings for Zosano Pharma.

Who are some of Zosano Pharma's key competitors?

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the folowing people:

  • John P. Walker, Chairman of the Board, President, Chief Executive Officer (Age 68)
  • Georgia L. Erbez, Interim Chief Financial Officer, Chief Business Officer (Age 49)
  • Eric Scharin, Vice President - Technical Operations
  • Thorsten von Stein M.D. Ph.D., Chief Medical Officer
  • Joseph P. Hagan, Director (Age 48)
  • Kenneth R. Greathouse, Independent Director
  • Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
  • Kleanthis G. Xanthopoulos Ph.D., Independent Director (Age 57)

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Who owns Zosano Pharma stock?

Zosano Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (13.08%) and Highlander Capital Management LLC (10.15%). Company insiders that own Zosano Pharma stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Kenneth Greathouse, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma.

Who bought Zosano Pharma stock? Who is buying Zosano Pharma stock?

Zosano Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Highlander Capital Management LLC and Victory Capital Management Inc.. Company insiders that have bought Zosano Pharma stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker, Kenneth Greathouse and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma.

How do I buy Zosano Pharma stock?

Shares of Zosano Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of Zosano Pharma stock can currently be purchased for approximately $4.35.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $9 million and generates $310,000.00 in revenue each year. The biotechnology company earns $-29,830,000.00 in net income (profit) each year or ($23.54) on an earnings per share basis. Zosano Pharma employs 38 workers across the globe.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 Ardentech Ct, FREMONT, CA 94555-3657, United States. The biotechnology company can be reached via phone at +1-510-7451200 or via email at [email protected]


MarketBeat Community Rating for Zosano Pharma (ZSAN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zosano Pharma (NASDAQ:ZSAN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $70.00$70.00$70.00$70.00
Price Target Upside: 97.74% upside97.74% upside97.74% upside97.74% upside

Zosano Pharma (NASDAQ:ZSAN) Consensus Price Target History

Price Target History for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ:ZSAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$80.00LowView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$60.00MediumView Rating Details
8/11/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Zosano Pharma (NASDAQ:ZSAN) Earnings History and Estimates Chart

Earnings by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ ZSAN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.24)N/AView Earnings Details
11/9/2017Q3 2017($3.00)($4.00)ViewN/AView Earnings Details
8/10/2017Q2 2017($3.00)($3.40)ViewN/AView Earnings Details
5/9/2017Q1 2017($6.00)($6.80)ViewListenView Earnings Details
3/1/2017Q4 2016($9.00)($9.20)ViewN/AView Earnings Details
11/9/2016Q3 2016($13.00)($10.40)ViewN/AView Earnings Details
8/10/2016Q2($10.00)($10.80)ViewN/AView Earnings Details
5/12/2016Q1($11.20)($13.60)ViewListenView Earnings Details
3/29/2016Q4($13.40)($12.80)ViewListenView Earnings Details
11/9/2015Q315($12.20)($14.40)$380.00 millionViewN/AView Earnings Details
8/12/2015Q215($10.60)($12.60)$0.22 million$0.10 millionViewN/AView Earnings Details
5/11/2015Q1 2015($8.60)($9.40)$0.50 million$0.22 millionViewN/AView Earnings Details
3/25/2015($12.80)($22.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Zosano Pharma (NASDAQ:ZSAN) Earnings Estimates

Current Year EPS Consensus Estimate: $-18 EPS
Next Year EPS Consensus Estimate: $-18 EPS

Dividends

Dividend History for Zosano Pharma (NASDAQ:ZSAN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Zosano Pharma (NASDAQ ZSAN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.95%
Insider Trades by Quarter for Zosano Pharma (NASDAQ:ZSAN)
Insider Trades by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ ZSAN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2017Kenneth GreathouseDirectorBuy55,000$0.61$33,550.00200,000View SEC Filing  
12/1/2017Kenneth GreathouseDirectorBuy95,000$0.62$58,900.0095,000View SEC Filing  
11/15/2017Kenneth GreathouseDirectorBuy50,000$0.62$31,000.0035,000View SEC Filing  
5/25/2017Georgia ErbezCFOBuy68,000$1.32$89,760.00115,750View SEC Filing  
5/25/2017John Peter WalkerCEOBuy73,716$1.36$100,253.76169,344View SEC Filing  
2/13/2017Enterprise Associates 12 NewMajor ShareholderSell1,099,996$2.01$2,210,991.96View SEC Filing  
9/16/2016Enterprise Associates 12 NewMajor ShareholderSell7,471$0.75$5,603.25View SEC Filing  
9/13/2016Enterprise Associates 12 NewMajor ShareholderSell10,000$0.74$7,400.00View SEC Filing  
8/29/2016M James BarrettMajor ShareholderSell50,000$1.01$50,500.005View SEC Filing  
8/24/2016Enterprise Associates 12 NewMajor ShareholderSell1,200$1.21$1,452.00View SEC Filing  
8/19/2016Donald J KellermanVPBuy15,920$1.32$21,014.4015,920View SEC Filing  
8/19/2016Georgia ErbezCFOBuy47,750$1.32$63,030.0047,750View SEC Filing  
8/19/2016John Peter WalkerDirectorBuy63,700$1.32$84,084.0063,700View SEC Filing  
8/19/2016Konstantinos AlatarisCEOBuy127,389$1.32$168,153.48View SEC Filing  
7/21/2016Enterprise Associates 12 NewMajor ShareholderSell23,681$1.27$30,074.87View SEC Filing  
7/13/2016Enterprise Associates 12 NewMajor ShareholderSell13,382$1.20$16,058.40View SEC Filing  
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zosano Pharma (NASDAQ ZSAN) News Headlines

Source:
DateHeadline
Zosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$4.80 Per ShareZosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$4.80 Per Share
www.americanbankingnews.com - February 21 at 5:24 AM
Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on TuesdayZosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:30 AM
ETF Preview: ETFs, Futures Point to Modest Gains Following CPI, Retail Sales DataETF Preview: ETFs, Futures Point to Modest Gains Following CPI, Retail Sales Data
www.nasdaq.com - February 14 at 9:37 AM
Zosano Pharma up 34% premarket ahead of stock offeringZosano Pharma up 34% premarket ahead of stock offering
seekingalpha.com - February 14 at 9:37 AM
Stock Review for Biotechs Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano PharmaStock Review for Biotech's Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma
www.bizjournals.com - February 6 at 9:34 AM
Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock SplitZosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
finance.yahoo.com - January 25 at 9:39 AM
-$0.24 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter-$0.24 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter
www.americanbankingnews.com - January 18 at 5:06 AM
Analysts Expect Zosano Pharma Corp (ZSAN) to Announce ($0.24) EPSAnalysts Expect Zosano Pharma Corp (ZSAN) to Announce ($0.24) EPS
www.americanbankingnews.com - January 13 at 5:06 PM
Zosano Pharma (ZSAN) Announces Notice of Allowance for US Patent Application Covering M207 as Acute Treatment ... - StreetInsider.comZosano Pharma (ZSAN) Announces Notice of Allowance for US Patent Application Covering M207 as Acute Treatment ... - StreetInsider.com
www.streetinsider.com - January 3 at 4:24 PM
Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for MigraineZosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
finance.yahoo.com - January 3 at 9:47 AM
Want To Invest In Zosano Pharma Corporation (NASDAQ:ZSAN)? Here’s How It Performed LatelyWant To Invest In Zosano Pharma Corporation (NASDAQ:ZSAN)? Here’s How It Performed Lately
finance.yahoo.com - January 2 at 5:05 PM
Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.24 Per ShareZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - January 1 at 11:22 AM
Zosano Pharma (ZSAN) Upgraded to "Sell" by ValuEngineZosano Pharma (ZSAN) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - December 31 at 11:04 PM
Reviewing Zosano Pharma (ZSAN) & Vertex Pharmaceuticals (VRTX)Reviewing Zosano Pharma (ZSAN) & Vertex Pharmaceuticals (VRTX)
www.americanbankingnews.com - December 17 at 7:28 PM
Brokerages Anticipate Zosano Pharma Corp (ZSAN) to Announce ($0.24) EPSBrokerages Anticipate Zosano Pharma Corp (ZSAN) to Announce ($0.24) EPS
www.americanbankingnews.com - December 17 at 1:50 AM
Alder BioPharmaceuticals (ALDR) vs. Zosano Pharma (ZSAN) Head-To-Head SurveyAlder BioPharmaceuticals (ALDR) vs. Zosano Pharma (ZSAN) Head-To-Head Survey
www.americanbankingnews.com - December 16 at 5:16 AM
Zosano Announces Resignation of Bruce Steel from Board of DirectorsZosano Announces Resignation of Bruce Steel from Board of Directors
finance.yahoo.com - December 15 at 4:35 PM
Zosano Pharma Corp (ZSAN) Director Acquires $33,550.00 in StockZosano Pharma Corp (ZSAN) Director Acquires $33,550.00 in Stock
www.americanbankingnews.com - December 8 at 6:22 PM
Zosano Pharma Corp (ZSAN) Director Kenneth Greathouse Purchases 95,000 SharesZosano Pharma Corp (ZSAN) Director Kenneth Greathouse Purchases 95,000 Shares
www.americanbankingnews.com - December 4 at 7:02 PM
Zacks: Brokerages Set $4.00 Price Target for Zosano Pharma Corp (ZSAN)Zacks: Brokerages Set $4.00 Price Target for Zosano Pharma Corp (ZSAN)
www.americanbankingnews.com - December 1 at 7:30 PM
Contrasting Zosano Pharma (ZSAN) & Seres Therapeutics (MCRB)Contrasting Zosano Pharma (ZSAN) & Seres Therapeutics (MCRB)
www.americanbankingnews.com - November 30 at 11:18 AM
Analyzing Zosano Pharma (ZSAN) and Dyax (DYAX)Analyzing Zosano Pharma (ZSAN) and Dyax (DYAX)
www.americanbankingnews.com - November 27 at 3:58 PM
 Zosano Pharma Corporation (ZSAN) Given Average Recommendation of "Strong Buy" by Brokerages Zosano Pharma Corporation (ZSAN) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 26 at 3:18 PM
Is Zosano Pharma Corporation (ZSAN) A Financially Sound Company?Is Zosano Pharma Corporation (ZSAN) A Financially Sound Company?
finance.yahoo.com - November 23 at 8:42 AM
Zosano Pharma Corporation (ZSAN) versus Opexa Therapeutics (ACER) Financial ContrastZosano Pharma Corporation (ZSAN) versus Opexa Therapeutics (ACER) Financial Contrast
www.americanbankingnews.com - November 19 at 9:28 PM
Kenneth Greathouse Acquires 50,000 Shares of Zosano Pharma Corporation (ZSAN) StockKenneth Greathouse Acquires 50,000 Shares of Zosano Pharma Corporation (ZSAN) Stock
www.americanbankingnews.com - November 16 at 9:25 PM
Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare ConferenceZosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 16 at 10:47 AM
Comparing KemPharm (KMPH) & Zosano Pharma Corporation (ZSAN)Comparing KemPharm (KMPH) & Zosano Pharma Corporation (ZSAN)
www.americanbankingnews.com - November 14 at 5:31 PM
Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational UpdateZosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update
finance.yahoo.com - November 12 at 1:47 PM
Zosano Pharma Corporation (ZSAN) Announces Quarterly  Earnings ResultsZosano Pharma Corporation (ZSAN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 10:52 PM
Zosano Pharma (ZSAN) Initiates Long-Term Safety Study for M207 as Acute Treatment of MigraineZosano Pharma (ZSAN) Initiates Long-Term Safety Study for M207 as Acute Treatment of Migraine
www.streetinsider.com - November 9 at 10:57 AM
Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of MigraineZosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine
finance.yahoo.com - November 9 at 10:57 AM
Comparing Zosano Pharma Corporation (ZSAN) & Its CompetitorsComparing Zosano Pharma Corporation (ZSAN) & Its Competitors
www.americanbankingnews.com - November 5 at 5:26 AM
Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update - GlobeNewswire (press release)Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update - GlobeNewswire (press release)
globenewswire.com - November 1 at 11:12 AM
Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational UpdateZosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update
finance.yahoo.com - November 1 at 11:12 AM
Zosano Pharma Corporation (ZSAN) Set to Announce Earnings on TuesdayZosano Pharma Corporation (ZSAN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
Zosano Pharma (ZSAN) Announces Stock Purchase Agreement with Lincoln Park Capital - StreetInsider.comZosano Pharma (ZSAN) Announces Stock Purchase Agreement with Lincoln Park Capital - StreetInsider.com
www.streetinsider.com - October 22 at 9:46 AM
Zosano Enters into Common Stock Purchase Agreement with Lincoln Park CapitalZosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital
finance.yahoo.com - October 21 at 10:13 AM
Zosano Pharma (ZSAN) Says Data of ADAM Zolmitriptan for Acute Treatment of Migraine Published in Cephalalgia - StreetInsider.comZosano Pharma (ZSAN) Says Data of ADAM Zolmitriptan for Acute Treatment of Migraine Published in Cephalalgia - StreetInsider.com
www.streetinsider.com - October 14 at 9:42 AM
Zosano Pharma (ZSAN) Says Data of ADAM Zolmitriptan for Acute Treatment of Migraine Published in CephalalgiaZosano Pharma (ZSAN) Says Data of ADAM Zolmitriptan for Acute Treatment of Migraine Published in Cephalalgia
www.streetinsider.com - October 13 at 10:37 AM
Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in CephalalgiaZosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia
finance.yahoo.com - October 13 at 10:37 AM
Todays Research Reports on Trending Tickers: Insys Therapeutics and Zosano Pharma CorporationToday's Research Reports on Trending Tickers: Insys Therapeutics and Zosano Pharma Corporation
finance.yahoo.com - October 11 at 9:55 AM
Zosano Appoints Kenneth Greathouse to Board of DirectorsZosano Appoints Kenneth Greathouse to Board of Directors
feeds.benzinga.com - October 4 at 9:25 AM
Zosano Provides Patent Application UpdateZosano Provides Patent Application Update
finance.yahoo.com - October 3 at 4:40 PM
Zosano Provides Patent Application Update - GlobeNewswire (press release)Zosano Provides Patent Application Update - GlobeNewswire (press release)
globenewswire.com - September 28 at 12:50 PM
Zosano Presents Data from ZOTRIP Study at International Headache SocietyZosano Presents Data from ZOTRIP Study at International Headache Society
finance.yahoo.com - September 14 at 12:11 PM
Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”
finance.yahoo.com - August 29 at 10:08 AM
 Analysts Expect Zosano Pharma Corporation (ZSAN) to Announce -$0.15 EPS Analysts Expect Zosano Pharma Corporation (ZSAN) to Announce -$0.15 EPS
www.americanbankingnews.com - August 25 at 4:10 AM
Zosano Pharmas (ZSAN) CEO John Walker on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaZosano Pharma's (ZSAN) CEO John Walker on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 12 at 9:06 AM
Zosano Pharma Corporation (ZSAN) vs. Acorda Therapeutics (ACOR) Head to Head ComparisonZosano Pharma Corporation (ZSAN) vs. Acorda Therapeutics (ACOR) Head to Head Comparison
www.americanbankingnews.com - August 11 at 4:58 PM

SEC Filings

Zosano Pharma (NASDAQ:ZSAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zosano Pharma (NASDAQ:ZSAN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zosano Pharma (NASDAQ ZSAN) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.